Do analysts recommend ZBH or STVN?

Zimmer Biomet presently has a consensus price target of $102.70, indicating a potential upside of 17.18%. Given Zimmer Biomet's higher possible upside, research analysts clearly believe Zimmer Biomet is more favorable than Stevanato Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zimmer Biomet 3 Sell rating(s) 12 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.26 Stevanato Group 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 2.86

Does the media prefer ZBH or STVN?

In the previous week, Zimmer Biomet had 4 more articles in the media than Stevanato Group. MarketBeat recorded 8 mentions for Zimmer Biomet and 4 mentions for Stevanato Group. Zimmer Biomet's average media sentiment score of 1.19 beat Stevanato Group's score of 0.86 indicating that Zimmer Biomet is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zimmer Biomet 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Stevanato Group 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend SOLV or STVN?

Solventum presently has a consensus price target of $84.25, indicating a potential upside of 13.64%. Given Solventum's higher possible upside, equities analysts clearly believe Solventum is more favorable than Stevanato Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Solventum 1 Sell rating(s) 5 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.50 Stevanato Group 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 2.86

Does the media prefer SOLV or STVN?

In the previous week, Stevanato Group had 1 more articles in the media than Solventum. MarketBeat recorded 4 mentions for Stevanato Group and 3 mentions for Solventum. Stevanato Group's average media sentiment score of 0.86 beat Solventum's score of 0.25 indicating that Stevanato Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solventum 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Stevanato Group 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer SNN or STVN?

Smith & Nephew SNATS currently has a consensus target price of $30.93, indicating a potential upside of 4.41%. Given Smith & Nephew SNATS's higher possible upside, equities analysts clearly believe Smith & Nephew SNATS is more favorable than Stevanato Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Smith & Nephew SNATS 0 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.17 Stevanato Group 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 2.86

Which has preferable valuation and earnings, SNN or STVN?

Smith & Nephew SNATS has higher revenue and earnings than Stevanato Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Smith & Nephew SNATS $6.16B 2.04 $625M N/A N/A Stevanato Group €1.34B 3.79 €158.21M €0.59 28.46

Do analysts prefer STVN or PEN?

Penumbra has a consensus price target of $361.33, suggesting a potential upside of 13.60%. Given Penumbra's higher probable upside, analysts plainly believe Penumbra is more favorable than Stevanato Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Stevanato Group 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 2.86 Penumbra 0 Sell rating(s) 14 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.18

Which has higher valuation & earnings, STVN or PEN?

Penumbra has higher revenue and earnings than Stevanato Group. Stevanato Group is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Stevanato Group €1.34B 3.79 €158.21M €0.59 28.46 Penumbra $1.40B 8.91 $177.69M $4.34 73.29

Is STVN or PEN more profitable?

Penumbra's return on equity of 10.87% beat Stevanato Group's return on equity. Company Net Margins Return on Equity Return on Assets Stevanato Group 11.76% 10.27% 6.08% Penumbra 11.76% 10.87% 8.45%

Does the media prefer STVN or PEN?

In the previous week, Stevanato Group had 2 more articles in the media than Penumbra. MarketBeat recorded 4 mentions for Stevanato Group and 2 mentions for Penumbra. Stevanato Group's average media sentiment score of 0.86 beat Penumbra's score of 0.68 indicating that Stevanato Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stevanato Group 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Penumbra 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate GKOS or STVN?

Glaukos currently has a consensus price target of $149.17, indicating a potential upside of 10.42%. Given Glaukos' higher probable upside, equities research analysts plainly believe Glaukos is more favorable than Stevanato Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Glaukos 1 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.79 Stevanato Group 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 2.86

Which has better valuation and earnings, GKOS or STVN?

Stevanato Group has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Glaukos $507.44M 15.64 -$187.69M -$3.28 N/A Stevanato Group €1.34B 3.79 €158.21M €0.59 28.46

Is GKOS or STVN more profitable?

Stevanato Group has a net margin of 11.76% compared to Glaukos' net margin of -34.34%. Stevanato Group's return on equity of 10.27% beat Glaukos' return on equity. Company Net Margins Return on Equity Return on Assets Glaukos -34.34% -6.92% -5.25% Stevanato Group 11.76% 10.27% 6.08%

Does the media favor GKOS or STVN?

In the previous week, Glaukos had 2 more articles in the media than Stevanato Group. MarketBeat recorded 6 mentions for Glaukos and 4 mentions for Stevanato Group. Glaukos' average media sentiment score of 0.99 beat Stevanato Group's score of 0.86 indicating that Glaukos is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glaukos 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Stevanato Group 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Stevanato Group (STVN) Competitors

€16.79 -0.15 (-0.89%)

Closing price 03:58 PM Eastern

Extended Trading

€16.85 +0.06 (+0.36%)

As of 06:42 PM Eastern

Compare

STVN vs. ZBH, SOLV, SNN, PEN, and GKOS

Should you buy Stevanato Group stock or one of its competitors? MarketBeat compares Stevanato Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Stevanato Group include Zimmer Biomet (ZBH), Solventum (SOLV), Smith & Nephew SNATS (SNN), Penumbra (PEN), and Glaukos (GKOS). These companies are all part of the "medical equipment" industry.

How does Stevanato Group compare to Zimmer Biomet?

Zimmer Biomet (NYSE:ZBH) and Stevanato Group (NYSE:STVN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, profitability, earnings and institutional ownership.

In the previous week, Zimmer Biomet had 4 more articles in the media than Stevanato Group. MarketBeat recorded 8 mentions for Zimmer Biomet and 4 mentions for Stevanato Group. Zimmer Biomet's average media sentiment score of 1.19 beat Stevanato Group's score of 0.86 indicating that Zimmer Biomet is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zimmer Biomet	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Stevanato Group	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Stevanato Group has a net margin of 11.76% compared to Zimmer Biomet's net margin of 9.05%. Zimmer Biomet's return on equity of 13.24% beat Stevanato Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zimmer Biomet	9.05%	13.24%	7.28%
Stevanato Group	11.76%	10.27%	6.08%

Zimmer Biomet presently has a consensus price target of $102.70, indicating a potential upside of 17.18%. Given Zimmer Biomet's higher possible upside, research analysts clearly believe Zimmer Biomet is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zimmer Biomet	3 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.26
Stevanato Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.86

88.9% of Zimmer Biomet shares are held by institutional investors. 1.3% of Zimmer Biomet shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Zimmer Biomet has a beta of 0.47, indicating that its stock price is 53% less volatile than the broader market. Comparatively, Stevanato Group has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market.

Zimmer Biomet has higher revenue and earnings than Stevanato Group. Zimmer Biomet is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zimmer Biomet	$8.41B	2.02	$705.20M	$3.85	22.76
Stevanato Group	€1.34B	3.79	€158.21M	€0.59	28.46

Summary

Zimmer Biomet beats Stevanato Group on 11 of the 17 factors compared between the two stocks.

How does Stevanato Group compare to Solventum?

Solventum (NYSE:SOLV) and Stevanato Group (NYSE:STVN) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, risk and institutional ownership.

Solventum presently has a consensus price target of $84.25, indicating a potential upside of 13.64%. Given Solventum's higher possible upside, equities analysts clearly believe Solventum is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solventum	1 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.50
Stevanato Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.86

Solventum has higher revenue and earnings than Stevanato Group. Solventum is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solventum	$8.26B	1.55	$1.56B	$8.16	9.09
Stevanato Group	€1.34B	3.79	€158.21M	€0.59	28.46

Solventum has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market. Comparatively, Stevanato Group has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market.

In the previous week, Stevanato Group had 1 more articles in the media than Solventum. MarketBeat recorded 4 mentions for Stevanato Group and 3 mentions for Solventum. Stevanato Group's average media sentiment score of 0.86 beat Solventum's score of 0.25 indicating that Stevanato Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solventum	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Stevanato Group	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Solventum has a net margin of 17.33% compared to Stevanato Group's net margin of 11.76%. Solventum's return on equity of 23.51% beat Stevanato Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solventum	17.33%	23.51%	7.63%
Stevanato Group	11.76%	10.27%	6.08%

Summary

Solventum beats Stevanato Group on 8 of the 15 factors compared between the two stocks.

How does Stevanato Group compare to Smith & Nephew SNATS?

Smith & Nephew SNATS (NYSE:SNN) and Stevanato Group (NYSE:STVN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment.

In the previous week, Stevanato Group had 4 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 4 mentions for Stevanato Group and 0 mentions for Smith & Nephew SNATS. Stevanato Group's average media sentiment score of 0.86 beat Smith & Nephew SNATS's score of 0.00 indicating that Stevanato Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Smith & Nephew SNATS	Neutral
Stevanato Group	Positive

Smith & Nephew SNATS has higher revenue and earnings than Stevanato Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Smith & Nephew SNATS	$6.16B	2.04	$625M	N/A	N/A
Stevanato Group	€1.34B	3.79	€158.21M	€0.59	28.46

Stevanato Group has a net margin of 11.76% compared to Smith & Nephew SNATS's net margin of 0.00%. Stevanato Group's return on equity of 10.27% beat Smith & Nephew SNATS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Smith & Nephew SNATS	N/A	N/A	N/A
Stevanato Group	11.76%	10.27%	6.08%

25.6% of Smith & Nephew SNATS shares are held by institutional investors. 1.0% of Smith & Nephew SNATS shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Smith & Nephew SNATS has a beta of 0.55, suggesting that its stock price is 45% less volatile than the broader market. Comparatively, Stevanato Group has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market.

Smith & Nephew SNATS currently has a consensus target price of $30.93, indicating a potential upside of 4.41%. Given Smith & Nephew SNATS's higher possible upside, equities analysts clearly believe Smith & Nephew SNATS is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Smith & Nephew SNATS	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17
Stevanato Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.86

Summary

Stevanato Group beats Smith & Nephew SNATS on 10 of the 15 factors compared between the two stocks.

How does Stevanato Group compare to Penumbra?

Stevanato Group (NYSE:STVN) and Penumbra (NYSE:PEN) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

Penumbra has a consensus price target of $361.33, suggesting a potential upside of 13.60%. Given Penumbra's higher probable upside, analysts plainly believe Penumbra is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stevanato Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.86
Penumbra	0 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18

Penumbra has higher revenue and earnings than Stevanato Group. Stevanato Group is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stevanato Group	€1.34B	3.79	€158.21M	€0.59	28.46
Penumbra	$1.40B	8.91	$177.69M	$4.34	73.29

88.9% of Penumbra shares are held by institutional investors. 2.9% of Penumbra shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Stevanato Group had 2 more articles in the media than Penumbra. MarketBeat recorded 4 mentions for Stevanato Group and 2 mentions for Penumbra. Stevanato Group's average media sentiment score of 0.86 beat Penumbra's score of 0.68 indicating that Stevanato Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stevanato Group	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Penumbra	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Stevanato Group has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market. Comparatively, Penumbra has a beta of 0.71, meaning that its share price is 29% less volatile than the broader market.

Penumbra's return on equity of 10.87% beat Stevanato Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stevanato Group	11.76%	10.27%	6.08%
Penumbra	11.76%	10.87%	8.45%

Summary

Penumbra beats Stevanato Group on 10 of the 15 factors compared between the two stocks.

How does Stevanato Group compare to Glaukos?

Glaukos (NYSE:GKOS) and Stevanato Group (NYSE:STVN) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability and analyst recommendations.

Stevanato Group has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$507.44M	15.64	-$187.69M	-$3.28	N/A
Stevanato Group	€1.34B	3.79	€158.21M	€0.59	28.46

Glaukos has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market. Comparatively, Stevanato Group has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market.

In the previous week, Glaukos had 2 more articles in the media than Stevanato Group. MarketBeat recorded 6 mentions for Glaukos and 4 mentions for Stevanato Group. Glaukos' average media sentiment score of 0.99 beat Stevanato Group's score of 0.86 indicating that Glaukos is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glaukos	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Stevanato Group	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Glaukos currently has a consensus price target of $149.17, indicating a potential upside of 10.42%. Given Glaukos' higher probable upside, equities research analysts plainly believe Glaukos is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
Stevanato Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.86

Stevanato Group has a net margin of 11.76% compared to Glaukos' net margin of -34.34%. Stevanato Group's return on equity of 10.27% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-34.34%	-6.92%	-5.25%
Stevanato Group	11.76%	10.27%	6.08%

99.0% of Glaukos shares are held by institutional investors. 5.9% of Glaukos shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Stevanato Group beats Glaukos on 9 of the 17 factors compared between the two stocks.

Get Stevanato Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

STVN vs. The Competition

Export

Metric	Stevanato Group	MED Industry	Medical Sector	NYSE Exchange
Market Cap	€5.08B	€2.97B	€6.47B	€23.14B
Dividend Yield	N/A	1.78%	2.68%	4.06%
P/E Ratio	28.46	18.43	24.71	31.08
Price / Sales	3.79	345.22	491.85	108.37
Price / Cash	19.88	55.91	27.92	18.65
Price / Book	3.03	4.11	10.82	4.65
Net Income	€158.21M	€64.45M	€3.56B	€1.07B
7 Day Performance	1.46%	2.24%	1.67%	-1.04%
1 Month Performance	-7.35%	1.04%	0.43%	0.18%
1 Year Performance	-28.92%	30.05%	32.84%	24.25%

Stevanato Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
STVN Stevanato Group	3.3545 of 5 stars	€16.79 -0.9%	N/A	-27.3%	€5.08B	€1.34B	28.46	6,010
ZBH Zimmer Biomet	4.7332 of 5 stars	$89.28 +1.2%	$102.70 +15.0%	-4.3%	$17.28B	$8.23B	23.20	17,000	Positive News
SOLV Solventum	3.4907 of 5 stars	$76.31 -0.8%	$84.25 +10.4%	-0.1%	$13.20B	$8.33B	9.34	20,000
SNN Smith & Nephew SNATS	2.0944 of 5 stars	$30.54 +0.2%	$30.93 +1.3%	+2.0%	$12.99B	$6.16B	N/A	16,988
PEN Penumbra	2.5313 of 5 stars	$318.40 +0.1%	$361.33 +13.5%	+23.3%	$12.52B	$1.40B	73.37	4,700

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:STVN) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Stevanato Group (STVN) Competitors

STVN vs. ZBH, SOLV, SNN, PEN, and GKOS

How does Stevanato Group compare to Zimmer Biomet?

Summary

How does Stevanato Group compare to Solventum?

Summary

How does Stevanato Group compare to Smith & Nephew SNATS?

Summary

How does Stevanato Group compare to Penumbra?

Summary

How does Stevanato Group compare to Glaukos?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STVN vs. The Competition

Stevanato Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Stevanato Group (STVN) Competitors

STVN vs. ZBH, SOLV, SNN, PEN, and GKOS

How does Stevanato Group compare to Zimmer Biomet?

Does the media prefer ZBH or STVN?

Is ZBH or STVN more profitable?

Do analysts recommend ZBH or STVN?

Do institutionals & insiders have more ownership in ZBH or STVN?

Which has more risk & volatility, ZBH or STVN?

Which has stronger earnings & valuation, ZBH or STVN?

Summary

How does Stevanato Group compare to Solventum?

Do analysts recommend SOLV or STVN?

Which has higher earnings and valuation, SOLV or STVN?

Which has more risk and volatility, SOLV or STVN?

Does the media prefer SOLV or STVN?

Is SOLV or STVN more profitable?

Summary

How does Stevanato Group compare to Smith & Nephew SNATS?

Does the media favor SNN or STVN?

Which has preferable valuation and earnings, SNN or STVN?

Is SNN or STVN more profitable?

Do institutionals & insiders have more ownership in SNN or STVN?

Which has more volatility & risk, SNN or STVN?

Do analysts prefer SNN or STVN?

Summary

How does Stevanato Group compare to Penumbra?

Do analysts prefer STVN or PEN?

Which has higher valuation & earnings, STVN or PEN?

Do institutionals and insiders hold more shares of STVN or PEN?

Does the media prefer STVN or PEN?

Which has more risk and volatility, STVN or PEN?

Is STVN or PEN more profitable?

Summary

How does Stevanato Group compare to Glaukos?

Which has better valuation and earnings, GKOS or STVN?

Which has more volatility & risk, GKOS or STVN?

Does the media favor GKOS or STVN?

Do analysts rate GKOS or STVN?

Is GKOS or STVN more profitable?

Do institutionals & insiders have more ownership in GKOS or STVN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STVN vs. The Competition

Stevanato Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools